Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.75 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.72 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.72 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.72 |
| ▸ | DHODH | Q02127 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinchophen SCHEMBL7588217 | 0.86 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| Cinchophen SCHEMBL29376617 | 0.86 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| Cinchophen SCHEMBL25519 | 0.86 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| SCHEMBL16921273 | 0.85 | DHODH (0.80) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| Cinchophen SCHEMBL10757475 | 0.85 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| Cinchophen SCHEMBL4805149 | 0.85 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| Cinchophen SCHEMBL4464779 | 0.85 | KDM4E (0.97) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| SCHEMBL4002319 | 0.84 | KDM4E (0.73) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| SCHEMBL4614391 | 0.84 | AKR1C3 (1.00) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 | |
| SCHEMBL17211764 | 0.84 | ALDH1A1 (0.69) | KDM4ELMNASMN1; SMN2PDE10AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | claimed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | claimed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | claimed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | claimed |
| US-11337968-B2 | Phenylquinoline compositions for treatment of ocular disorders and conditions | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2017189958-A1 | PHENYLQUINOLINE COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS AND CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1416931-B1 | INHIBITORS OF POLYQ-AGGREGATION | MAX PLANCK GESELLSCHAFT (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259887-A1 | INHIBITORS OF POLYQ-AGGREGATION | HTT, ATXN2, ATXN2L | KDM4E 2734/4885LMNA 384/4885SMN1; SMN2 36/4885 |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | HTT, ATXN2, ATXN2L | KDM4E 2734/4885LMNA 384/4885SMN1; SMN2 36/4885 |
| US-11337968-B2 | Phenylquinoline compositions for treatment of ocular disorders and conditions | PPARG, PPARA, PPARD | KDM4E 3677/4885LMNA 635/4885SMN1; SMN2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.